Insight Molecular Diagnostics Advances GraftAssureDx FDA Review
NASHVILLE, Tennessee, August 10, 2026 Insight Molecular Diagnostics, Inc. (iMDx) reported second-quarter 2026 results and provided an update on...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NASHVILLE, Tennessee, August 10, 2026 Insight Molecular Diagnostics, Inc. (iMDx) reported second-quarter 2026 results and provided an update on...
Menlo Park, California – August 4, 2026 Sight Sciences, Inc. has announced that the U.S. Food and Drug Administration...
Ipswich, Massachusetts – August 4, 2026 New England Biolabs (NEB®) has expanded its molecular biology portfolio with the launch...
VENLO, Netherlands & GERMANTOWN, Md., May 28, 2026 QIAGEN announced the availability of two custom-designed research-use-only (RUO) QIAcuity digital...
BOSTON, April 16, 2026 Foundation Medicine, Inc. has announced a major expansion of its oncology diagnostics portfolio through the...
